KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Liabilities (2016 - 2025)

Moderna (MRNA) has disclosed Total Liabilities for 10 consecutive years, with $3.7 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 13.79% to $3.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, up 13.79% year-over-year, with the annual reading at $3.7 billion for FY2025, 13.79% up from the prior year.
  • Total Liabilities for Q4 2025 was $3.7 billion at Moderna, up from $2.8 billion in the prior quarter.
  • The five-year high for Total Liabilities was $10.8 billion in Q3 2021, with the low at $2.6 billion in Q2 2025.
  • Average Total Liabilities over 5 years is $6.0 billion, with a median of $5.1 billion recorded in 2023.
  • The sharpest move saw Total Liabilities surged 1975.62% in 2021, then tumbled 50.05% in 2023.
  • Over 5 years, Total Liabilities stood at $10.5 billion in 2021, then plummeted by 36.0% to $6.7 billion in 2022, then crashed by 32.12% to $4.6 billion in 2023, then dropped by 29.11% to $3.2 billion in 2024, then increased by 13.79% to $3.7 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.7 billion, $2.8 billion, and $2.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.